Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty
American Journal of Hematology · 2023
DOI: 10.1002/ajh.26994 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Tzu-Fei Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Ottawa at The Ottawa Hospital, Ottawa, Ontario, Canada. Hauptthemen laut MEDLINE: Venous Thromboembolism, Arthroplasty, Replacement, Knee, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Chronic kidney disease (CKD) confers a high risk of thrombosis and bleeding. However, little evidence exists regarding the optimal choice of postoperative thromboprophylaxis in these patients. We conducted a population‐based, retrospective cohort study among adults ≥66 years old with CKD undergoing hip or knee arthroplasty who had filled an outpatient prophylactic anticoagulant prescription between 2010 and 2020 in Ontario, Canada. The primary outcomes of venous thrombosis (VTE) and hemorrhage were identified by validated algorithms using relevant diagnoses and billing codes. Overlap‐weighted cause‐specific Cox proportional hazard models were used to examine the association of direct oral anticoagulants (DOAC) on the 90‐day risk of VTE and hemorrhage compared with low‐molecular‐weight heparin (LMWH). A total of 27 645 patients were prescribed DOAC ( N = 22 943) or LMWH ( N = 4702) after arthroplasty. Rivaroxaban was the predominant DOAC (94.5%), while LMWH mainly included enoxaparin (67%) and dalteparin (31.5%). DOAC users had higher eGFRs, fewer co‐morbidities, and surgery in more recent years compared to LMWH users. After weighing, DOAC (compared with LMWH) was associated with a lower risk of VTE (DOAC: 1.5% vs. LMWH: 2.1%, weighted hazard ratio [HR] 0.75, 95% confidence interval [CI] 0.59–0.94) and a higher risk of hemorrhage (DOAC: 1.3% vs. LMWH: 1.0%, weighted HR 1.44, 95% CI 1.04–1.99). Additional analyses including a more stringent VTE defining algorithm, different eGFR cut‐offs, and limiting to rivaroxaban and enoxaparin showed consistent findings. Among elderly adults with CKD, DOAC was associated with a lower VTE risk and a higher hemorrhage risk compared to LMWH following hip or knee arthroplasty.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Ottawa at The Ottawa Hospital, Ottawa, Ontario, Canada.
- Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
- ICES, Toronto, Ontario, Canada.
- Division of Hematology, Department of Medicine, Western University, London, Ontario, Canada.
- Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
- Bruyère Research Institute, Ottawa, Ontario, Canada.
ORCID-Profile: Tzu-Fei Wang, Marc Carrier, Aurélien Delluc, Manish M Sood
Zitieren
APA
Wang, T. F., Grubic, N., Carrier, M., Canney, M., Delluc, A., Hundemer, G. L., Knoll, G., Lazo-Langner, A., Massicotte-Azarniouch, D., Tanuseputro, P., & Sood, M. M. (2023). Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty. American Journal of Hematology. https://doi.org/10.1002/ajh.26994
Vancouver
Wang TF, Grubic N, Carrier M, Canney M, Delluc A, Hundemer GL, et al. Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty. American Journal of Hematology. 2023. doi:10.1002/ajh.26994
BibTeX
@article{Wang2023,
author = {Wang, Tzu-Fei and Grubic, Nicholas and Carrier, Marc and Canney, Mark and Delluc, Aurélien and Hundemer, Gregory L and Knoll, Gregory and Lazo-Langner, Alejandro and Massicotte-Azarniouch, David and Tanuseputro, Peter and Sood, Manish M},
title = {Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty},
journal = {American Journal of Hematology},
year = {2023},
doi = {10.1002/ajh.26994}
}
EUVIMED